Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

AIMS: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Clin Pharmacol
Hoofdauteurs: Assouline, Sarit, Buccheri, Valeria, Delmer, Alain, Gaidano, Gianluca, McIntyre, Christine, Brewster, Michael, Catalani, Olivier, Hourcade-Potelleret, Florence, Sayyed, Pakeeza, Badoux, Xavier
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Ltd 2015
Onderwerpen:
Clinical Trials
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631173/
https://ncbi.nlm.nih.gov/pubmed/25900065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12662
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items